Clinical Trials in Romania

• A double blinded, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence stud… Pending
  2025-521598-16-00 ulcerative colitis Sun Pharmaceutical Industries Limited
• Phase 3 trial of VMX-C001 vs usual pharmacological care in patients taking a FXa direct oral anticoagulant who require urgent surgery with o… Pending
  2025-521632-12-00 Phase III Patients on Factor Xa inhibitor treatment needing an urgent … VarmX B.V.
• An Open-Label Study of ML-007C-MA in Adults with Alzheimer’s Disease Psychosis Pending
  2025-521757-16-00 Phase II Hallucinations and Delusions Associated with Alzheimer’s Dis… Maplight Therapeutics Inc.
• Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants Pending
  2025-521758-40-00 Phase I Geographic Atrophy Regeneron Pharmaceuticals Inc.
• A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with In… Pending
  2025-521769-29-00 Phase III Pulmonary Hypertension Associated with Interstitial Lung Dis… Insmed Inc.
• IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after… Pending
  2025-521908-22-00 Phase II/III EGFR-mutated Non-small Cell Lung Cancer Bristol-Myers Squibb Services Unlimited Company
• A double blinded, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence stud… Pending
  2025-522106-20-00 ulcerative colitis Sun Pharmaceutical Industries Limited
• A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P… Pending
  2025-522471-28-00 Phase III psoriatic arthritis (PsA) MoonLake Immunotherapeutics AG
• An extension study to investigate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chr… Pending
  2025-522983-33-00 Phase III Chronic rhinosinusitis with nasal polyps Sanofi-Aventis Recherche & Developpement
• An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover, bioavailability study comparing Bupropi… Pending
  2025-523410-84-00 Seasonal affective disorder Sun Pharmaceutical Industries Limited
• An open label, balanced, randomized, three treatment, three period, three sequence, single dose, crossover study to assess the effect of foo… Pending
  2025-523411-11-00 Phase I (Other) Seasonal affective disorder Sun Pharmaceutical Industries Limited
• A Phase 1/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, a… Pending
  2025-523590-42-00 Phase I (FiH) Locally Advanced or Metastatic Solid Tumors Crescent Biopharma Inc.
• Phase 1b study to assess the safety and tolerability of SR-878 in patients with rheumatoid arthritis Pending
  2025-523678-17-00 Phase I (Other) rheumatoid arthritis SciRhom GmbH
• A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (13 to 17 years of age) Pending
  2025-523711-11-00 Phase III Schizophrenia Bristol-Myers Squibb Services Unlimited Company
• Efficacy and safety of vamifeport in adult subjects with HFE-related hereditary hemochromatosis Pending
  2025-523793-16-00 Phase II Homeostatic iron regulator gene-related hereditary hemochrom… CSL Behring LLC
• A study of BMN 333 versus Vosoritide in Children with Achondroplasia Pending
  2025-523811-12-00 Phase II/III Achondroplasia Biomarin Pharmaceutical Inc.
• A Study of Enpatoran in Cutaneous Manifestations of Lupus With or Without Systemic Disease Pending
  2025-523871-44-00 Phase III Cutaneous Manifestations of Lupus Erythematosus With or With… Merck Healthcare KGaA
• Phase 3 Evaluation of KarXT and KarXT+KarX-EC in Schizophrenia and Autism-Related Irritability in Youth, respectively. Pending
  2025-524062-16-00 Phase III Schizophrenia and Autism Spectrum Disorder (ASD) Bristol-Myers Squibb Services Unlimited Company
• A phase 3 study of orelabrutinib in combination with rituximab plus bendamustine (BR) compared with BR in subjects with treatment-naїve mant… Pending
  2025-524241-27-00 Phase III Treatment-naїve mantle cell lymphoma (MCL) Innocare Pharma Inc.
• An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Trametin… Pending
  2025-524267-20-00 Adjuvant treatment of BRAF V600E or V600K mutation-positive … Sun Pharmaceutical Industries Limited
• BETRI-Prospective: Asthma control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 µg]) vs Single Inhaler ICS/LABA (200/… Pending
  2025-524289-56-00 Phase IV Asthma Chiesi Farmaceutici S.p.A.
• A Phase 3 Study of Orelabrutinib in Non-active Secondary Progressive Multiple Sclerosis Pending
  2025-524322-18-00 Phase III Non-active Secondary Progressive Multiple Sclerosis (SPMS) Zenas Biopharma (USA) LLC
• Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combination for Inflammatory Bowel Disease Pending
  2025-524640-35-00 Phase II Ulcerative colitis (Inflammatory Bowel Disease) Spyre Therapeutics Inc.
• Phase 1 Single Dose Study of JADE201 in Participants with Rheumatoid Arthritis Pending
  2025-524746-96-00 Phase I Rheumatoid Arthritis Jade Biosciences Inc.

Showing 25–48 of 865 trials